Sequenom Gets Rights to Genetic Test for Vision Disorder

Xconomy San Diego — 

San Diego-based Sequenom (NASDAQ: SQNM) says it has obtained rights to develop and commercialize a diagnostic test from New Haven, CT-based Optherion to predict a patient’s genetic predisposition to late-stage, age-related macular degeneration, a progressive eye disorder that can lead to a loss of central vision. Financial terms of the licensing agreement were not disclosed. Once the test is developed, Sequenom says it plans to market the new test next year under its SensiGene brand for genetic tests.